Biocon's new monoclonal antibodies facility in India get manufacturing approval from EMA 0 24.06.2024 07:04 Business Standard Biocon said that its subsidiary Biocon Biologics has received approval from the European Medicines Agency (EMA) to manufacture biosimilar Bevacizumab at its new multi-product monoclonal antibodies (mAbs) drug substance facility at Bengaluru. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа
